PCK2 and colonic neoplasm: A dual PCK1 and PCK2 inhibitor that was efficient in reducing subcutaneous colon cancer growth in vivo was recently found to be well-tolerated without inducing weight loss, albeit slightly reducing basal glucose levels in starved mice [93].